Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors
Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer
Gleevec Approval Sets Record For FDA Review: 73 Days
Advances Found In Treatment Of Aerodigestive Cancers
Silicone Implants Not Linked To Increased Risk Of Death
B-14 Trial: No Advantage To 10 Years Of Tamoxifen
NCI-Approved Clinical Trials Listed For April 2001
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- No need for a speculum? A new era of HPV screening
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally









